Lonza appoints chief operating officer

Company: Lonza

For Life Science Ingredients (LSI) business

Lonza has appointed Harry Boot as chief operating officer for its Life Science Ingredients (LSI) sector and member of the Lonza management committee. He takes over the position from Stefan Borgas, who has headed the sector ad interim since June 2010, parallel to his position as chief executive. Boot will take up the role on 1 March.

Boot brings significant global experience and knowledge to Lonza having previously worked at GE Silicones, GE Plastics, GE Consumer & Industrial and most recently Bluestar/ Blackstone, where he was chief commercial officer. He has managed large organisations and has a strong sales, marketing and operational background. He has a degree in mechanical engineering and an MBA in Finance.

Boot has lived in Asia since 2005. After a short transition period in Basel, Switzerland, he will relocate back to China.

You may also like

Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Lonza to supply prequalified cells for CN Bio OOC technology

Organ-on-a-chip technology has the potential to solve the issues presented by 2D cell cultures and animal models, the companies say
Ingredients

Lonza announces cryopreserved Leukopak offering

Fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation, limiting transportation options
Ingredients

Lonza introduces hi-res HLA-typed primary cell lots

This offering builds on the company’s human primary cell capabilities
Ingredients

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to quickly assess new drug candidates while minimising API consumption
Subscribe now